Download PDF
Horm Metab Res 2022; 54(12): 859-865
DOI: 10.1055/a-1926-7364
Original Article: Endocrine Research

Tripartite Motif Containing 26 is a Positive Predictor for Endometrial Carcinoma Patients and Regulates Cell Survival in Endometrial Carcinoma

Tanmin Lu
1   Department of Gynecology and Obstetrics, Liaocheng People’s Hospital, Liaocheng City, China
,
Yu Wu
1   Department of Gynecology and Obstetrics, Liaocheng People’s Hospital, Liaocheng City, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Functioning as an E3 ubiquitin ligase, tripartite motif containing 26 (TRIM26) can regulate the tumor behavior and the relevant inflammatory immune response. Endometrial carcinoma is a major gynecological malignant tumor in the world, while no relevant research has been performed. KMplot, a web-based survival analysis tool, demonstrated that TRIM26 expression was positively correlated with the overall survival in gynecological tumors, such as ovarian, cervical, and endometrial cancer. The relatively low expression of TRIM26 was also found in endometrial cancer tissues and endometrial cancer cell lines. In the online Gene Expression Profiling Interactive Analysis (GEPIA) platform, TRIM26 was positively correlated with the pre-apoptosis genes of p53, BIM, BID, BAX, and BAK, and negatively correlated with the anti-apoptosis gene of BCLW. To further explore the function of TRIM26 in endometrial carcinoma, Ishikawa and KLE cells were infected with PLVX-TRIM26-derived lentivirus. TRIM26 overexpression suppressed the growth of endometrial cells, with downregulated p-AKT and upregulated BIM and BID expression. PLVX-TRIM26 overexpressed Ishikawa cells were injected subcutaneously into the side flanks of male BALB/C nude mice to construct a TRIM26-overexpression xenograft model. TRIM26 overexpression suppressed the growth of endometrial cancer as indicated by downregulated tumor volume and tumor weight with downregulated p-AKT expression. TRIM26 could regulate AKT pathway and apoptosis process to inhibit the growth of endometrial carcinoma, which can be utilized as a survival predictor.

Key words

endometrial carcinoma - TRIM26 - cell growth - apoptosis - AKT signaling


Publication History

Received: 30 May 2022

Accepted after revision: 11 August 2022

Article published online:
15 September 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Loukovaara M, Pasanen A, Bützow R. Molecular classification of endometrial carcinoma: a clinically oriented review. J Clin Pathol 2022; DOI: 10.1136/jclinpath-2022-208345. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 2 Constantine GD, Kessler G, Graham S. et al. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larchmt) 2019; 28: 237-243
    CrossrefPubMedGoogle Scholar
  • 3 Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med 2020; 383: 2053-2064
    CrossrefPubMedGoogle Scholar
  • 4 Zhou WJ, Zhang J, Yang HL. et al. Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. Cell Commun Signal 2019; 17: 99
    CrossrefPubMedGoogle Scholar
  • 5 Shaw E, Farris M, McNeil J. et al. Obesity and endometrial cancer. Recent Results Cancer Res 2016; 208: 107-136
    CrossrefPubMedGoogle Scholar
  • 6 Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician 2016; 93: 468-474
    PubMedGoogle Scholar
  • 7 Venuto S, Merla G. E3 Ubiquitin ligase TRIM proteins, cell cycle and mitosis. Cells 2019; 8: 510
    CrossrefPubMedGoogle Scholar
  • 8 Liu L, Yin S, Brobbey C. et al. Ubiquitination in cancer stem cell: roles and targeted cancer therapy. STEMedicine 2020; 1: e37
    CrossrefPubMedGoogle Scholar
  • 9 Wang K, Chai L, Qiu Z. et al. Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells. J Cell Physiol 2019; 234: 19019-19027
    CrossrefPubMedGoogle Scholar
  • 10 Wang Y, He D, Yang L. et al. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis. Biochem Biophys Res Commun 2015; 463: 458-465
    CrossrefPubMedGoogle Scholar
  • 11 Tao JL, Luo M, Sun H. et al. Overexpression of tripartite motif containing 26 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling. Kaohsiung J Med Sci 2020; 36: 417-422
    CrossrefPubMedGoogle Scholar
  • 12 Xie X, Li H, Pan J. et al. Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt/GSK3beta/beta-catenin pathway. Chem Biol Interact 2021; 337: 109366
    CrossrefPubMedGoogle Scholar
  • 13 Zhao J, Cai B, Shao Z. et al. TRIM26 positively regulates the inflammatory immune response through K11-linked ubiquitination of TAB1. Cell Death Differ 2021; 28: 3077-3091
    CrossrefPubMedGoogle Scholar
  • 14 Ran Y, Zhang J, Liu L-L. et al. Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune response. J Mol Cell Biol 2015; 8: 31-43
    CrossrefPubMedGoogle Scholar
  • 15 Deligdisch L, Marin T, Lee AT. et al. Human mammary tumor virus (HMTV) in endometrial carcinoma. Int J Gynecol Cancer 2013; 23: 1423-1428
    CrossrefPubMedGoogle Scholar
  • 16 Wang L, Li X, Ren Y. et al. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Cancer Sci 2019; 110: 1609-1620
    CrossrefPubMedGoogle Scholar
  • 17 Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci 2017; 42: 297-311
    CrossrefPubMedGoogle Scholar
  • 18 Wang S, Zhang Y, Huang J. et al. TRIM67 activates p53 to suppress colorectal cancer initiation and progression. Cancer Res 2019; 79: 4086-4098
    CrossrefPubMedGoogle Scholar
  • 19 Yin H, Li Z, Chen J. et al. Expression and the potential functions of TRIM32 in lung cancer tumorigenesis. J Cell Biochem 2019; 120: 5232-5243
    CrossrefPubMedGoogle Scholar
  • 20 Sun J, Zhang T, Cheng M. et al. TRIM29 facilitates the epithelial-to-mesenchymal transition and the progression of colorectal cancer via the activation of the Wnt/beta-catenin signaling pathway. J Exp Clin Cancer Res 2019; 38: 104
    CrossrefPubMedGoogle Scholar
  • 21 Qiu F, Xiong JP, Deng J. et al. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol 2015; 8: 5053-5061
    PubMedGoogle Scholar
  • 22 Xu W, Chen B, Ke D. et al. TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin. Aging (Albany N Y) 2020; 12: 13488-13501
    PubMedGoogle Scholar
  • 23 Ai L, Kim WJ, Alpay M. et al. TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res 2014; 74: 4875-4887
    CrossrefPubMedGoogle Scholar
  • 24 Tan ST, Liu SY, Wu B. TRIM29 Overexpression promotes proliferation and survival of bladder cancer cells through NF-kappaB signaling. Cancer Res Treat 2016; 48: 1302-1312
    CrossrefPubMedGoogle Scholar
  • 25 Sun H, Dai X, Han B. TRIM29 as a novel biomarker in pancreatic adenocarcinoma. Dis Markers 2014; 2014: 317817
    PubMedGoogle Scholar
  • 26 Zhou XM, Sun R, Luo DH. et al. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway. Oncotarget 2016; 7: 13634-13650
    CrossrefPubMedGoogle Scholar
  • 27 Masuda Y, Takahashi H, Sato S. et al. TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun 2015; 6: 7299
    CrossrefPubMedGoogle Scholar
  • 28 Li X, Yuan J, Song C. et al. Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma. Cell Death Differ 2021; 28: 2315-2332
    CrossrefPubMedGoogle Scholar